International Journal of Molecular Sciences,
Год журнала:
2022,
Номер
23(8), С. 4351 - 4351
Опубликована: Апрель 14, 2022
Alzheimer’s
disease
(AD),
an
elderly
neurodegenerative
disorder
with
a
high
incidence
and
progressive
memory
decline,
is
one
of
the
most
expensive,
lethal,
burdening
diseases.
To
date,
pathogenesis
AD
has
not
been
fully
illustrated.
Emerging
studies
have
revealed
that
cellular
senescence
abnormal
glucose
metabolism
in
brain
are
early
hallmarks
AD.
Moreover,
disturbance
patients
may
precede
amyloid-β
deposition
or
Tau
protein
phosphorylation.
Thus,
metabolic
reprogramming
targeting
senescent
microglia
astrocytes
be
novel
strategy
for
intervention
treatment.
Here,
we
recapitulate
relationships
between
neural
cell
(e.g.,
insulin
signaling,
lactate
metabolism)
We
then
discuss
potential
perspective
towards
intervention,
providing
theoretical
basis
further
exploration
therapeutic
approach
toward
Chemical Society Reviews,
Год журнала:
2021,
Номер
51(2), С. 513 - 565
Опубликована: Дек. 10, 2021
We
discuss
novel
approaches
for
embracing
and
reproducing
complexity
of
Tau
pathology
required
developing
disease-relevant
diagnostics
effective
therapies.
Bioengineering & Translational Medicine,
Год журнала:
2022,
Номер
8(1)
Опубликована: Авг. 3, 2022
Abstract
Alzheimer's
disease
(AD)
and
Parkinson's
(PD)
are
the
most
prevalent
neurodegenerative
diseases,
affecting
millions
costing
billions
each
year
in
United
States
alone.
Despite
tremendous
progress
developing
therapeutics
that
manage
symptoms
of
these
two
scientific
community
has
yet
to
develop
a
treatment
effectively
slows
down,
inhibits,
or
cures
neurodegeneration.
To
gain
better
understanding
current
therapeutic
frontier
for
AD
PD,
we
provide
review
on
past
present
strategies
major
disorders
clinical
trial
process.
We
briefly
recap
currently
US
Food
Drug
Administration‐approved
therapies,
then
explore
trends
trials
across
variables
therapy
mechanism
intervention,
administration
route,
use
delivery
vehicle,
outcome
measures,
phases
over
time
“Drug”
“Biologic”
therapeutics.
success
rate
analyze
intersections
approaches
revealing
shift
away
from
therapies
targeting
neurotransmitter
systems
symptomatic
relief,
towards
anti‐aggregation,
anti‐inflammatory,
anti‐oxidant,
regeneration
aim
inhibit
root
causes
progression.
also
highlight
evolving
distribution
types
investigated,
slowly
increasing
still
severe
under‐utilization
vehicles
PD
discuss
novel
preclinical
treating
PD.
Overall,
this
aims
succinct
overview
landscape
understand
field's
strategy
evolution
approach
present,
inform
how
treat
future.
World Psychiatry,
Год журнала:
2023,
Номер
22(1), С. 48 - 74
Опубликована: Янв. 14, 2023
Despite
considerable
progress
in
pharmacotherapy
over
the
past
seven
decades,
many
mental
disorders
remain
insufficiently
treated.
This
situation
is
part
due
to
limited
knowledge
of
pathophysiology
these
and
lack
biological
markers
stratify
individualize
patient
selection,
but
also
a
still
restricted
number
mechanisms
action
being
targeted
monotherapy
or
combination/augmentation
treatment,
as
well
variety
challenges
threatening
successful
development
testing
new
drugs.
In
this
paper,
we
first
provide
an
overview
most
promising
drugs
with
innovative
that
are
undergoing
phase
2
3
for
schizophrenia,
bipolar
disorder,
major
depressive
anxiety
trauma‐related
disorders,
substance
use
dementia.
Promising
repurposing
established
medications
psychiatric
indications,
variations
modulation
dopamine,
noradrenaline
serotonin
receptor
functioning,
considered.
We
then
critically
discuss
clinical
trial
parameters
need
be
considered
depth
when
developing
pharmacological
agents
treatment
disorders.
Hurdles
perils
success
drug
include
inadequacy
imprecision
inclusion/exclusion
criteria
ratings,
sub‐optimally
suited
participants,
multiple
factors
contributing
large/increasing
placebo
effect,
problems
statistical
analyses.
information
should
order
de‐risk
programmes
novel
known
increasing
their
chances
success.
JAMA Neurology,
Год журнала:
2022,
Номер
79(5), С. 478 - 478
Опубликована: Март 28, 2022
Several
anti-amyloid
monoclonal
antibodies
have
been
developed
for
slowing
the
progression
of
Alzheimer
disease
(AD).
Among
furthest
are
aducanumab,
which
received
accelerated
approval
from
US
Food
and
Drug
Administration
in
2021,
donanemab,
is
currently
undergoing
phase
3
trials.
The
cost-effectiveness
these
treatments
has
not
established.
International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(4), С. 3895 - 3895
Опубликована: Фев. 15, 2023
Alzheimer's
disease
(AD)
is
the
most
common
form
of
dementia
and
may
contribute
to
60-70%
cases.
Worldwide,
around
50
million
people
suffer
from
prediction
that
number
will
more
than
triple
by
2050,
as
population
ages.
Extracellular
protein
aggregation
plaque
deposition
well
accumulation
intracellular
neurofibrillary
tangles,
all
leading
neurodegeneration,
are
hallmarks
brains
with
disease.
Therapeutic
strategies
including
active
passive
immunizations
have
been
widely
explored
in
last
two
decades.
Several
compounds
shown
promising
results
many
AD
animal
models.
To
date,
only
symptomatic
treatments
available
because
alarming
epidemiological
data,
novel
therapeutic
prevent,
mitigate,
or
delay
onset
required.
In
this
mini-review,
we
focus
on
our
understanding
pathobiology
discuss
current
immunomodulating
therapies
targeting
amyloid-β
protein.
